Eviplera

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Lambert-Niclot S, Allavena C, Grude M,
J Antimicrob Chemother. 2016 May 26.
Abstract
FULL-TEXT ARTICLE
Hepatic Safety of Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate Fixed-Dose Single-Tablet Regimen in HIV-Infected Patients with Active Hepatitis C Virus Infection: The hEPAtic Study.
Neukam K, Espinosa N, Collado A, et al
PLoS One. 2016 May 19;11(5):e0155842
Paper
FULL-TEXT ARTICLE
Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study
Porter DP, Daeumer M, Thielen A, et a;
Viruses. 2015 Dec 7;7(12):6360-70.
Paper
Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.
Gianotti N, Poli A, Nozza S, Spagnuolo V, et al
J Int AIDS Soc. 2015 Jul 30;18(1):20037.
Abstract
Single-tablet emtricitabine-rilpivirine-tenofovir as HIV post-exposure prophylaxis in men who have sex with men.
Foster R, McAllister J, Read TR, et al
Clin Infect Dis. 2015 Jun 29.
Abstract
Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Kabbara WK, Ramadan WH.
J Infect Public Health. 2015 May 19.
Abstract
Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
Brunetta J, Moreno Guill�n S, et al
Patient. 2015 Mar 26
Abstract
Lipids and Cardiovascular Risk After Switching HIV-1 Patients on Nevirapine and Emtricitabine/Tenofovir-DF to Rilpivirine/Emtricitabine/Tenofovir-DF.
Rokx C, Verbon A, Rijnders BJ.
AIDS Res Hum Retroviruses. 2015 Jan 27.
Abstract
Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort.
Pinnetti C, Di Giambenedetto S, Maggiolo F, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19812.
Abstract
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR study.
Podzamczer D, Rozas N, Domingo P, et al
J Int AIDS Soc. 2014 Nov 2;17(4(Suppl 3)):19814
Abstract
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Wyatt CM, Kitch D, Gupta SK, et al
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):36-44
Abstract
The Combined Anti-HIV-1 Activity of Emtricitabine and Tenofovir with the Integrase Inhibitors Elvitegravir or Raltegravir Show High Levels of Synergy In Vitro.
Kulkarni R, Hluhanich R, McColl DM, et al
Antimicrob Agents Chemother. 2014 Aug 4.
Abstract
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Allavena C, Dailly E, Reliquet V, et al
J Antimicrob Chemother. 2014 Jun 6.
Abstract
Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Na�ve HIV-1-Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis.
Behrens G, Rijnders B, Nelson M, et al
AIDS Patient Care STDS. 2014 Apr;28(4):168-75.
Abstract
Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
Custodio JM, Yin X, Hepner M, et al
J Clin Pharmacol. 2014 Apr;54(4):378-85.
Abstract
Characterization of HIV-1 Drug Resistance Development Through Week 48 in Antiretroviral Naive Subjects on Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF in the STaR Study (GS-US-264-0110).
Porter DP, Kulkarni R, Fralich T, et al
J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):318-26
Abstract
Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.
Cohen C, Wohl D, Arribas JR, Henry K, et al AIDS. 2014 Feb 6
Abstract
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Lambert-Niclot S, Charpentier C, Storto A, et al
J Antimicrob Chemother. 2013 Dec 2
Abstract
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM, Cohen C, Dejesus E, et al
HIV Clin Trials. 2013 Sep-Oct;14(5):216-33
Abstract
FULL=TEXT ARTICLE
Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera�/Eviplera�) in the treatment of HIV infection.
Bernardini C, Maggiolo F.
Patient Prefer Adherence. 2013 Jun 19;7:531-
Abstract
Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet
of emtricitabine, rilpivirine, and tenofovir.
Wainberg MA. HIV AIDS (Auckl). 2013;5:41-9.
Abstract
Safety and efficacy of fixed-dose combination rilpivirine-tenofovir-emtricitabine (RPV/TDF/FTC) in treatment-experienced patients infected with HIV-1.
Cevik M, Sonecha S, Nelson M.
J Int AIDS Soc. 2012 Nov 11;15(6):18291.
Abstract
STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-na�ve adults.
Cohen C, Wohl D, Arribas J, et al
J Int AIDS Soc. 2012 Nov 11;15(6):18221.
Abstract
Effect of food on the pharmacokinetics of emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen.
Ramanathan S, Custodio J, Yin X, et al
J Int AIDS Soc. 2012 Nov 11;15(6):18333
Abstract
Budget impact analysis of introducing the new single-tablet regimen rilpivirine/emtricitabine/tenofovir for the treatment of HIV in Portugal.
Gouveia M, Costa J, Te�filo E, Borges M.
J Int AIDS Soc. 2012 Nov 11;15(6):18375
Abstract
STRike - characteristics of HIV-1-infected patients treated with a single-tablet regimen in daily clinical practice.
Esser S, Heiken H, Gallo L, et al
J Int AIDS Soc. 2012 Nov 11;15(6):18356
Abstract
FULL-TEXT ARTICLE
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of
rilpivirine-emtricitabine-tenofovir.
Patel N, Miller CD.
HIV AIDS (Auckl). 2012;4:61-71.
Paper
Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen:
A Guide to Its Use in HIV-1 Infection.
Lyseng-Williamson KA, Scott LJ. et al
Clin Drug Investig. 2012 Oct 1;32(10):715-22
Abstract
FULL-TEXT ARTICLE
New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose
combination of rilpivirine-emtricitabine-tenofovir.
Patel N, Miller CD.
HIV AIDS (Auckl). 2012;4:61-71
Paper
Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
De Clercq E.
Biochem Pharmacol. 2012 Apr 5.
Abstract
Pharmacokinetics of Emtricitabine, Tenofovir, and GS-9137 Following Coadministration of
Emtricitabine/Tenofovir Disoproxil Fumarate and Ritonavir-Boosted GS-9137.
Ramanathan S, Shen G, Cheng A, Kearney BP.
J Acquir Immune Defic Syndr. 2007 Mar 29;
Abstract